Results 201 to 210 of about 601,571 (336)

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Unraveling Abdominal Distention: A Rare Presentation of Giant Pancreatic Mucinous Cystic Neoplasm in a Patient With Cystic Fibrosis. [PDF]

ACG Case Rep J
Nageswaran G, Ton L, Chandrasekar VT, Yap JEL.   +3 more
europepmc   +1 more source

Induction of mammary neoplasms in the ACI rat by 430-keV neutrons, X-rays, and diethylstilbestrol [PDF]

, 1982
Chmelevsky, D., Holtzman, S., Kellerer, Albrecht M., Shellabarger, C. J., Stone, J. P.   +4 more
core   +1 more source

On the Use of Radon in the Treatment of Neoplasms of the Skin [PDF]

, 1930
R. T. Brain
openalex   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias, Ana Oitabén, Sonia Zumalave, Bernardo Rodriguez‐Martin, María Gallardo‐Gómez, Martín Santamarina, Ana Pequeño‐Valtierra, Laura Juaneda‐Magdalena, Ramón García‐Escudero, José Luis López‐Cedrún, Máximo Fraga, José M. C. Tubio, Mónica Martínez‐Fernández   +12 more
wiley   +1 more source

A Dual-Feature Framework for Enhanced Diagnosis of Myeloproliferative Neoplasm Subtypes Using Artificial Intelligence. [PDF]

Bioengineering (Basel)
Bamaqa A, Labeeb NS, El-Gendy EM, Ibrahim HM, Farsi M, Balaha HM, Badawy M, Elhosseini MA.   +7 more
europepmc   +1 more source

Advanced Osteo-Arthropathy in a Case of Pulmonary Neoplasm [PDF]

, 1930
Harold Avery
openalex   +1 more source

RETRACTION: lncRNA‐PDPK2P Promotes Hepatocellular Carcinoma Progression Through the PDK1/AKT/Caspase 3 Pathway

Molecular Oncology, EarlyView.
RETRACTION: W. Pan, W. Li, J. Zhao, Z. Huang, J. Zhao, S. Chen, C. Wang, Y. Xue, F. Huang, Q. Fang, J. Wang, D. Brand, and S. G. Zheng, “lncRNA‐PDPK2P Promotes Hepatocellular Carcinoma Progression Through the PDK1/AKT/Caspase 3 Pathway,” Molecular Oncology 13, no. 10 (2019): 2246–2258, https://doi.org/10.1002/1878-0261.12553.
wiley   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Mediastinal Neoplasm with Secondary Glandular Enlargement in the Neck [PDF]

, 1929
Cecil P. G. Wakeley
openalex   +1 more source